Abstract:Helicobacter pylori (HP) is a major causative agent of chronic gastritis and peptic ulcer. HP is also engaged in the development of gastric cancer and gastric mucosa-associated lymphoid tissue lymphoma. It is an important pathogenic factor in various other systemic diseases, such as vitamin B12 deficiency, iron deficiency, and idiopathic thrombocytopenia. The current consensus is that unless there is a special reason, eradication therapy should be implemented whenever HP infection is found, and it is ideally successful the first time. International guidelines recommend that under certain conditions, treatment should be personalized based on drug susceptibility testing. However, drug susceptibility testing is often not available because it is expensive, time-consuming, and difficult to obtain living tissue. Each region has separately formulated guidelines or consensuses on empirical therapy. Owing to an increasing drug resistance rate in various places, the eradication rate of proton pump inhibitor (PPI) triple therapy and sequential therapy has been affected. These regimens are rarely used; the PPI triple especially has been abandoned in most areas. Currently, radical treatment regimens for HP involve bismuth-containing quadruple therapy and concomitant therapy. However, quadruple therapy has its own limitations, such as complex drug administration. To improve the effectiveness, safety, and compliance, many clinical studies have proposed useful modified regimens, which mainly include the modified bismuth-containing quadruple regimen, high-dose dual therapy, and vonoprazan-containing regimens. Studies have shown that these emerging regimens have acceptable eradication rates and safety, and are expected to become first-line treatments in empirical therapy. However, the problem of decline in the eradication rate caused by drug resistance has not been fundamentally solved. This review not only summarizes the effectiveness of mainstream regimens in the first-line treatment of HP infection with the currently increasing antibiotic resistance rates, but also summarizes the effectiveness and safety of various emerging treatment regimens.

Progress of diagnosis and treatment schemes of Helicobacter pylori infection

Efficacy of quadruple therapy with clarithromycin based on faecal molecular antimicrobial susceptibility tests as first-line treatment for <i>Helicobacter pylori</i> infection: a protocol of a single-centre, single-blind, randomised clinical trial in China

Current Status of Helicobacter Pylori Eradication and Risk Factors for Eradication Failure

Antibiotic resistance of Helicobacter pylori isolated in the Southeast Coastal Region of China.

Recent progress in Helicobacter pylori treatment

Treatment of Helicobacter pylori infection——current challenges

The Actuality and Expectation on Helicobacter Pylori Infection Treatment

Helicobacter Pylori Infection: A Recent Approach to Diagnosis and Management

Is Tailored Therapy Based on Antibiotic Susceptibility Effective ? a Multicenter, Open-Label, Randomized Trial

Seven-day triple therapy is a better choice for Helicobacter pylori eradication in regions with low antibiotic resistance.

Treatment strategies and pharmacist‐led medication management for Helicobacter pylori infection

The effect of antibiotic resistance on Helicobacter pylori eradication efficacy: A systematic review and meta‐analysis

Anti-Helicobacter pylori with traditional Chinese medicine:the innovative perspectives

Study of Antibiotic Resistance of 108 Helicobacter pylori Strains and the Role of the Resistant Strains in Cure of Helicobacter pylori Infection

Treatment of Helicobacter pylori Infection: Current Status and Considerations

Treatment of Helicobacter pylori infection: Past, present and future

Progress of anti-Helicobacter pylori therapy in clinic

The status and progress of first-line treatment against Helicobacter pylori infection: a review

Helicobacter pylori infection: an overview in 2013, focus on therapy.

Innovative Perspectives of Integrated Chinese Medicine on H-pylori

Regimens and Influencing Factors of Helicobacter pylori Eradication